|
Neuronal Ceroid Lipofuscinosis Combi ( NCL Combi )
Test number: 8133
Gene: NCL
Price: £ 66.00 (including VAT)
|
|
Note |
This test detects 2 mutations depending on the selected breed:
- In Australian Shepherd and Miniature American Shepherd:
2 breed specific variants are detected (standard and adult onset)
- In Australian Cattle Dog : 2 breed specific variants are detected (standard and adult onset)
- In Dachshunds : 2 breed specific variants are detected (standard and adult onset)
Please note that other breeds are known to be affected by other NCL variants, you can check
NCL in other breeds |
|
|
|
|
|
|
|
|
Breeds
|
|
Australian Cattle Dog
,
Australian Shepherd
,
Dachshund
,
Miniature Wire haired Dachshund
,
Miniature American Shepherd
,
Miniature Long Haired Dachshund
,
Miniature Smooth Haired Dachshund
,
Standard Long Haired Dachshund
,
Standard Smooth Haired Dachshund
,
Standard Wirehaired Dachshund
.
|
|
|
|
The Disease |
|
The clinical course includes increasing levels of agitation and possible outbursts of aggression, hallucinations, hyperactivity and epileptic fits. Most animals lose their ability to coordinate everyday muscular activities. As the extent of neurodegeneration increases, all affected dogs develop psychological abnormalities and ataxia.
|
|
|
|
|
Trait of Inheritance |
|
Ceroid lipofuscinosis in Border Collies and American Bulldogs is an inherited autosomal recessive trait. This means that a dog can be clear (homozygous normal), affected, or a carrier (heterozygous). The carriers can spread the diseased gene in the population. Therefore, reliable information on non-affected dogs is the key to controlling this disease.
|
Inheritance : AUTOSOMAL
RECESSIVE
trait
Sire
|
|
Dam
|
|
Offspring
|
| |
|
|
|
|
|
clear
|
 |
clear
|
 |
100% clear
|
| |
|
|
|
|
|
clear
|
|
carrier
|
|
50% clear + 50%
carriers
|
| |
|
|
|
|
|
clear
|
|
affected
|
|
100% carriers
|
| |
|
|
|
|
|
carrier
|
|
clear
|
|
50% clear + 50%
carriers
|
| |
|
|
|
|
|
carrier
|
|
carrier
|
|
25% clear + 25% affected
+ 50% carriers
|
| |
|
|
|
|
|
carrier
|
|
affected
|
|
50% carriers + 50%
affected
|
| |
|
|
|
|
|
affected
|
|
clear
|
|
100% carriers
|
| |
|
|
|
|
|
affected
|
|
carrier
|
|
50% carriers + 50%
affected
|
| |
|
|
|
|
|
affected
|
|
affected
|
|
100% affected
|
Clear
Genotype: N / N [ Homozygous normal ]
The dog is noncarrier of the mutant gene.
It is very unlikely that the dog will develop Neuronal Ceroid Lipofuscinosis Combi ( NCL Combi ). The dog will never pass the mutation to its offspring, and therefore it can be bred to any other dog.
Carrier
Genotype: N / NCL [ Heterozygous ]
The dog carries one copy of the mutant gene and one
copy of the normal gene.
It is very unlikely that the dog will develop Neuronal Ceroid Lipofuscinosis Combi ( NCL Combi ) but since it carries the mutant gene, it can pass it on to its offspring with the probability of 50%. Carriers should only be bred to clear dogs. Avoid breeding carrier to carrier because 25% of their offspring is expected to be affected (see table above)
Affected
Genotype: NCL / NCL [ Homozygous mutant ]
The dog carries two copies of the mutant gene and
therefore it will pass the mutant gene to its entire offspring.
The dog is likely to develop Neuronal Ceroid Lipofuscinosis Combi ( NCL Combi ) and will pass the mutant gene to its entire offspring
|
|
|
|
Description |
|
The mutation-based gene test and its advantages
The genetic defect leading to the disease has been identified. By DNA testing, the responsible mutation can be shown directly. This method provides a very high accuracy test and can be done at any age. It offers the possibility to distinguish not only between affected and clear dogs, but also to identify clinically healthy carriers. This is an essential information for controlling the disease in the breed, as carriers are able to spread the disease in the population, but can not be identified by means of common laboratory diagnostic. * Please note that NCL in American Staffordhsire Terrier is run by a partner lab
|
|
|
|
| |
| |
|
Price
|
|
£ 66.00 (including VAT)
|
|
|
 |
|
|
|
|
